WarrenDavidShlomchikMD
Oncology • Pittsburgh, PAHematologic Oncology
Associate Professor, Comprehensive Cancer Center, Yale University School of Medicine
Dr. Shlomchik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Avenue
BST E1552
Pittsburgh, PA 15232
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 1993 - 1997
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
Perelman School of Medicine at the University of PennsylvaniaClass of 1989
Certifications & Licensure
PA State Medical License 1993 - 2024
CT State Medical License 2000 - 2015
NY State Medical License 1991 - 1994
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD Start of enrollment: 2009 Dec 17
- Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD Start of enrollment: 2015 Feb 03
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) Start of enrollment: 2019 Nov 19
Publications & Presentations
PubMed
- 769 citationsGraft-versus-host disease.Warren D. Shlomchik
Nature Reviews. Immunology. 2007-05-01 - 959 citationsPrevention of graft versus host disease by inactivation of host antigen-presenting cells.Warren D. Shlomchik, Matthew S. Couzens, Cheng Bi Tang, Jennifer M. McNiff, Marie E. Robert
Science. 1999-07-16 - 426 citationsEpidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity.Daniel H. Kaplan, Mathew C. Jenison, S Saeland, Warren D. Shlomchik, Mark J. Shlomchik
Immunity. 2005-12-01
Press Mentions
Novel Transplant Approach Improves the Odds for Leukemia PatientsJanuary 10th, 2022
Grant Support
- Leukemia Stem Cells: Essential Targets For GVL And Mediators Of Gvl-ResistanceNational Cancer Institute2009–2012
- Role Of Tissue Antigen Presenting Cells In GVHDNational Heart, Lung, And Blood Institute2011
- Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2010
- Dendritic Cell Subsets And Paths Of Maturation In Graft-Vs.-Host Disease (GVHD)National Heart, Lung, And Blood Institute2007–2010
- Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Institute Of Allergy And Infectious Diseases2006–2009
- Graft Versus Leukemia Against Murine Chronic Phase &Blast Crisis CMLNational Cancer Institute2007
- Dendritic Cell Subsets And Paths Of Maturation In GVHDNational Heart, Lung, And Blood Institute2006
- GVL Against Murine Chronic Phase And Blast Crisis CMLNational Cancer Institute2003–2006
- Novel Immunotoxins For Depletion Of Dendritic CellsNational Heart, Lung, And Blood Institute2005
- Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1999–2002
- Pathogenic Mechanisms Of GVD In Murine ModelNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2000
- Alloimmunity To CML In A Novel Murine ModelNational Heart, Lung, And Blood Institute1998
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
